Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study.

被引：0
|
作者：
Shamash, J.
Jacob, J.
Powles, T.
Agrawal, S.
Mutsvangwa, K.
Saunders, N.
Wilson, P.
Stebbing, J.
机构：
[1] St Bartholomews Hosp, London, England
[2] Univ London Imperial Coll Sci Technol & Med, London, England
[3] St Barthlomews Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.2573
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2573
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase I study of imatinib mesylate (IM) and sorafenib (S) in patients (pts) with refractory castration-resistant prostate cancer (CRPC).
    Nabhan, Chadi
    Villines, Dana
    Valdez, Tina V.
    Tolzien, Kathy
    Lestingi, Timothy M.
    Bitran, Jacob D.
    Susan, Christner M.
    Egorin, Merrill J.
    Beumer, Jan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [23] Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
    Wang, Jue
    McGuire, Timothy R.
    Schwarz, James K.
    Meza, Jane L.
    Talmadge, James E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [24] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Pedro C. Barata
    Matthew Cooney
    Prateek Mendiratta
    Allison Tyler
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 1085 - 1092
  • [25] A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085)
    Yu, E.
    Massard, C.
    Gross, M.
    Wilding, G.
    Posadas, E.
    Culine, S.
    Carducci, M. A.
    Trudel, G.
    Paliwal, P.
    Sternberg, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC)
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Wang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Zhang, Hongyong
    Wang, Yu
    Ghosh, Paramita
    Lara, Primo N., Jr.
    Pasquinelli, Patricia
    Beckett, Laurel
    White, Ralph W. deVere
    Pan, Chong-Xian
    CANCER RESEARCH, 2010, 70
  • [28] A phase I/II randomized study of panobinostat and bicalutamide in castration-resistant prostate cancer (CRPC) patients progressing on second-line hormone therapy
    Ferrari, A. C.
    Stein, M. N.
    Alumkal, J. J.
    Gomez-Pinillos, A.
    Catamero, D. D.
    Mayer, T. M.
    Collins, F.
    Beer, T. M.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [29] Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC).
    Anand, Aseem
    Danila, Daniel Costin
    Heller, Glenn
    Herkal, Amrita
    Patel, Chintan
    Khanin, Raya
    Schultz, Nikolaus
    Lilja, Hans
    Fleisher, Martin
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial
    Pan, C.
    Ghosh, P.
    Suga, J. M.
    Paequinelli, P.
    Beckett, L.
    White, R. Deere
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345